Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) has received a consensus recommendation of "Buy" from the eight brokerages that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $206.67.
Several research analysts have weighed in on KRYS shares. Chardan Capital reiterated a "buy" rating and set a $212.00 price objective on shares of Krystal Biotech in a research report on Wednesday, December 18th. HC Wainwright reaffirmed a "buy" rating and set a $221.00 price target on shares of Krystal Biotech in a research report on Wednesday, December 18th. Citigroup boosted their price objective on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a "neutral" rating in a report on Tuesday, November 5th. Finally, Stifel Nicolaus increased their target price on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a "buy" rating in a research report on Wednesday, September 11th.
View Our Latest Report on Krystal Biotech
In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the transaction, the insider now directly owns 1,475,882 shares in the company, valued at $243,195,835.96. The trade was a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 14.10% of the company's stock.
A number of institutional investors have recently modified their holdings of the business. Bank of New York Mellon Corp boosted its stake in Krystal Biotech by 115.7% in the second quarter. Bank of New York Mellon Corp now owns 193,767 shares of the company's stock valued at $35,583,000 after buying an additional 103,928 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Krystal Biotech by 3.9% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,461 shares of the company's stock valued at $819,000 after purchasing an additional 169 shares during the last quarter. Principal Financial Group Inc. increased its position in Krystal Biotech by 1,972.0% during the 2nd quarter. Principal Financial Group Inc. now owns 123,469 shares of the company's stock worth $22,674,000 after purchasing an additional 117,510 shares in the last quarter. Crossmark Global Holdings Inc. bought a new position in Krystal Biotech in the 2nd quarter valued at approximately $319,000. Finally, CIBC Asset Management Inc bought a new position in Krystal Biotech in the 2nd quarter valued at approximately $250,000. Institutional investors and hedge funds own 86.29% of the company's stock.
KRYS opened at $156.66 on Wednesday. The stock has a market cap of $4.51 billion, a PE ratio of 88.51 and a beta of 0.80. The stock's fifty day simple moving average is $177.54 and its 200 day simple moving average is $184.50. Krystal Biotech has a 1-year low of $107.50 and a 1-year high of $219.34.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.07. The firm had revenue of $83.84 million for the quarter, compared to analysts' expectations of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The business's revenue was up 879.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.67) EPS. Equities analysts forecast that Krystal Biotech will post 2.97 earnings per share for the current year.
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.